Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Threolone vs Synthomycine vs Aqua Cream for EGFR-I Induced Rash
NCT01256437Phase 2
Key facts
- Status
- Completed
- Start
- Jan 2011
- Primary completion
- Jan 2017
- Countries
- 1
- Sponsor
- Rabin Medical Center
- Modality
- Small Molecules
- Conditions
- acneiform eruption
01
Overview
Phase 2, randomised, double-blind trial of chloramphenicol + prednisolone in acneiform eruption (3 arms), sponsored by Rabin Medical Center. Primary endpoint: Number of patients developing grade 2 / above rash at 3 years. Started Jan 2011; status: completed.
02
Design
3 arms- Study design
- RandomizedDouble-blind
Threolone
Threolone ointment once daily
Synthomycine
Synthomycine ointment once daily
Aqua Cream
Aqua cream ointment once daily
03
Who it enrols
Patients planned to initiate treatment with EGFR inhibitors (cetuximab, erlotinib, gefitinib, or panitumumab) without prior facial topical treatment or rash.
04
Endpoints
Primary
Number of patients developing grade 2 / above rash
Secondary
Number of patients developing a rash
Beyond the preview
Go deeper on NCT01256437.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01256437.